Trump's Medicare Plan for Obesity Drugs Raises Concerns Over Longevity
Starting July 1, Medicare will provide GLP-1 weight-loss drugs at a cost of $50. While intended as a temporary measure, its permanence is questionable.
Editorial Staff
1 min read
Updated 2 days ago
Beginning July 1, Medicare is set to offer GLP-1 weight-loss drugs for a fee of $50. This initiative is framed as a temporary program.
However, there are growing concerns that once implemented, the program may be difficult to discontinue.
The implications of this plan could affect Medicare's budget and the accessibility of these drugs in the long term.